Market Movers

Gilead Sciences, Inc.’s Stock Price Drops to $125.84, Reflecting a 1.31% Decrease: A Detailed Performance Analysis

By November 29, 2025 No Comments

Gilead Sciences, Inc. (GILD)

125.84 USD -1.67 (-1.31%) Volume: 3.06M

Gilead Sciences, Inc.’s stock price stands at 125.84 USD, experiencing a slight dip of -1.31% this trading session, with a trading volume of 3.06M. Despite the day’s decline, GILD stocks maintain a robust performance, showcasing a considerable YTD increase of +38.04%.


Latest developments on Gilead Sciences, Inc.

Gilead Sciences, Inc. has been making headlines recently with various key events leading up to today’s stock price movements. Johnson Financial Group Inc. recently bought over 4,000 shares of Gilead Sciences, Inc. stock, showing confidence in the biotech company. Gilead Sciences also announced plans for an 800,000 square foot expansion at its Foster City headquarters, indicating strong growth prospects. Additionally, the company teamed up with Sweden’s Sprint for its latest oncology pact, further bolstering its position in the industry. Oak Associates Ltd. in Ohio raised its position in Gilead Sciences, Inc., while Te Ahumairangi Investment Management Ltd purchased over 9,000 shares. On the other hand, Verity & Verity LLC sold a significant amount of Gilead Sciences, Inc. shares. These developments have contributed to the fluctuations in Gilead Sciences, Inc. stock price today.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars